Human umbilical cord‐derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction

Liu, Bo; Ding, Fengxia; Yang, Lu; Geng, Xin; Lin, Tao; He, Dalin; Zhang, Yuanyuan; Zhang, Deying; Wei, Guanghui

doi:10.1111/nep.13099

Cited by 41 publications

(35 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, DNA oxidation and lipid peroxidation caused by cisplatin‐induced kidney damage are alleviated by exosomes from human umbilical cord‐derived MSCs (UC‐MSCs); these results were confirmed in vitro with renal proximal tubular cells 27 . Treatments with MSCs were also demonstrated to reduce levels of ROS in animal models of diabetic retinopathy and nephropathy, severe acute pancreatitis, ureteral obstruction‐induced kidney damage, Alzheimer's disease, and metabolic renovascular disease 24,28‐32 . Specifically, MSC treatments have been shown to reduce levels of H 2 O 2 in intestinal inflammation and several organs in a model of premature aging 33,34 .…”

Section: Effect Of Mscs On Oxidative Stress Biomarkers and Rosmentioning

confidence: 89%

“…Administration of MSCs has been demonstrated to reduce levels of one or more of these markers in a variety of animal models associated with oxidative stress (Table 1). Injection of MSCs themselves may not be critical to their antioxidant effects as administration of their conditioned medium (CM) also reduced lipid peroxidation in a model of ureteral obstruction‐induced kidney injury 24 . Administration of MSC‐derived exosomes was also effective to rescue protein oxidation and lipid peroxidation in animal models of septic and hyperglycemic brain injury and cognitive impairment 25,26 .…”

Section: Effect Of Mscs On Oxidative Stress Biomarkers and Rosmentioning

confidence: 99%

See 1 more Smart Citation

The emerging antioxidant paradigm of mesenchymal stem cell therapy

Stavely

Nurgali

2020

Stem Cells Translational Medicine

135

101

View full text Add to dashboard Cite

Mesenchymal stem cells (multipotent stromal cells; MSCs) have been under investigation for the treatment of diverse diseases, with many promising outcomes achieved in animal models and clinical trials. The biological activity of MSC therapies has not been fully resolved which is critical to rationalizing their use and developing strategies to enhance treatment efficacy. Different paradigms have been constructed to explain their mechanism of action, including tissue regeneration, trophic/anti‐inflammatory secretion, and immunomodulation. MSCs rarely engraft and differentiate into other cell types after in vivo administration. Furthermore, it is equivocal whether MSCs function via the secretion of many peptide/protein ligands as their therapeutic properties are observed across xenogeneic barriers, which is suggestive of mechanisms involving mediators conserved between species. Oxidative stress is concomitant with cellular injury, inflammation, and dysregulated metabolism which are involved in many pathologies. Growing evidence supports that MSCs exert antioxidant properties in a variety of animal models of disease, which may explain their cytoprotective and anti‐inflammatory properties. In this review, evidence of the antioxidant effects of MSCs in in vivo and in vitro models is explored and potential mechanisms of these effects are discussed. These include direct scavenging of free radicals, promoting endogenous antioxidant defenses, immunomodulation via reactive oxygen species suppression, altering mitochondrial bioenergetics, and donating functional mitochondria to damaged cells. Modulation of the redox environment and oxidative stress by MSCs can mediate their anti‐inflammatory and cytoprotective properties and may offer an explanation to the diversity in disease models treatable by MSCs and how these mechanisms may be conserved between species.

show abstract

Section: Effect Of Mscs On Oxidative Stress Biomarkers and Rosmentioning

confidence: 89%

Section: Effect Of Mscs On Oxidative Stress Biomarkers and Rosmentioning

confidence: 99%

The emerging antioxidant paradigm of mesenchymal stem cell therapy

Stavely

Nurgali

2020

Stem Cells Translational Medicine

135

101

View full text Add to dashboard Cite

show abstract

“…Zhang et al [41] reported that MSC effectively reduced the level of MDA, and increased SOD in the lung tissue of acute lung injury rats. Liu et al [42] reported that MSC significantly increased the activity of glutathione (GSH), and reduced the levels of MDA in rats induced by unilateral ureteral obstruction.…”

Section: Discussionmentioning

confidence: 99%

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Zhou

Lin

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. Results 27 studies were eligible and recruited for this meta-analysis. The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6-8 days, 10-15 days, ≥42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P=0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P<0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P<0.0001; 6-8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P=0.0005; 10-15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P<0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P=0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2-3 days, 4-5 days, 6-8 days, ≥28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion: MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

show abstract

“…Zhang et al [41] reported that MSC effectively reduced the level of MDA, and increased SOD in the lung tissue of acute lung injury rats. Liu et al [42] reported that MSC signi cantly increased the activity of glutathione (GSH), and reduced the levels of MDA in rats induced by unilateral ureteral obstruction.…”

Section: Discussionmentioning

confidence: 99%

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Zhou

Lin

Liao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Renal damage caused by drug toxicity is becoming more and more common in clinic. How to avoid and treat kidney damage caused by drug toxicity is essential to maintain patient health and reduce social economic burden. In this study, we performed a meta-analysis to assess the nephroprotective effect of mesenchymal stem cells (MSCs) in therapy of kidney disease induced by toxicant. Methods Cochrane Library, Embase, ISI Web of Science and PubMed databases were searched up to Dec 31, 2019 to identify the studies and extract the data to assess the efficacy of MSCs for kidney disease induced by toxicant using Cochrane Review Manager Version 5.3. Results 27 studies were eligible and recruited for this meta-analysis. The results showed that the difference of Scr between MSCs treatment group and control group was notable for 2 days, 4 days, 5 days, 6–8 days, 10–15 days, ≥ 42 days (2 days: WMD =-0.88, 95%CI: -1.34, -0.42, P = 0.0002; 4 days: WMD=-0.69, 95%CI: -0.99, -0.39, P < 0.00001; 5 days: WMD=-0.46, 95%CI: -0.67, -0.25, P < 0.0001; 6–8 days: WMD=-0.51, 95%CI: -0.79, -0.22, P = 0.0005; 10–15 days: WMD =-0.38, 95%CI: -0.56, -0.20, P < 0.0001; ≥42 days: WMD =-0.22, 95%CI: -0.39, -0.06, P = 0.007). Furthermore, the difference of BUN between MSCs treatment group and control group was notable for 2–3 days, 4–5 days, 6–8 days, ≥ 28 days. The results also indicated that MSCs treatment can alleviate the inflammatory cells, necrotic tubule, regenerative tubules, renal interstitial fibrosis in kidney disease induced by toxicant. Conclusion MSCs might be a promising therapeutic agent for kidney disease induced by toxicant.

show abstract

Human umbilical cord‐derived mesenchymal stem cells conditioned medium attenuate interstitial fibrosis and stimulate the repair of tubular epithelial cells in an irreversible model of unilateral ureteral obstruction

Abstract: This study shows that CM protects UUO-induced kidney damage and therefore could be a potential tool to prevent CKD progression.

Cited by 41 publications

References 25 publications

The emerging antioxidant paradigm of mesenchymal stem cell therapy

The emerging antioxidant paradigm of mesenchymal stem cell therapy

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Nephroprotective effect of mesenchymal stem cells in therapy of kidney disease induced by toxicant

Contact Info

Product

Resources

About